The Russian Ministry of Health has granted permission to carry out a clinical trial for an innovative drug targeting Crohn’s disease and ulcerative colitis, created by Russian Biocad. In the initial phase, the effects of the development, known as BCD-261, will be tested on healthy men aged 18 to 45.
The research will take place at a specialized research center in St. Petersburg. In the first phase, researchers intend to establish a therapeutic dose of the drug, and its effectiveness and safety will be assessed in the second and third phases, which will involve patients with Crohn’s disease and moderate to severe ulcerative colitis.
In the future, Biocad plans to evaluate the effectiveness of the development in the treatment of children. According to the Russian Children’s Clinical Hospital, there are more than 500 thousand patients with ulcerative colitis and Crohn’s disease living in the country, including more than 10 thousand children.
